Vernalis (VER)

 

VER Share PerformanceMore

52 week high51.500 25/04/16
52 week low20.000 21/04/17
52 week change -28.500 (-56.30%)
4 week volume6,400,142 28/03/17

Technical Insight

Login or Register to access technical insights.

Latest NewsMore

Broker Forecast - Panmure Gordon issues a broker note on Vernalis PLC

Panmure Gordon today downgrades its investment rating on Vernalis PLC (LON:VER) to hold (from buy) and left its pri...

Broker Forecast - Stifel issues a broker note on Vernalis PLC

Stifel today reaffirms its hold investment rating on Vernalis PLC (LON:VER) and cut its price target to 24p (from 29p).

FTSE struggles as dominant blue-chips fall

Weakness in pharmaceutical stocks AstraZeneca (AZN) and Hikma (HIK), as well as consumer goods giants Reckitt Benck...

FTSE ahead as miners up with industrial metals prices

London shares are making minor gains in early deals with multi-commodity miners benefiting from rises in industrial m...

Vernalis to resubmit NDA to US FDA for drug CCP-07

Vernalis said a complete response letter (CRL) from the US FDA did not raise any concerns with the formulation or pharm...

Vernalis receives $2 million milestone payment

RNS Number: 9220C Vernalis PLC 21 April 2017 21 April 2017 LSE: VER Vernalis plc receives a $2 million milestone payment from one of its drug discovery collaborations Vernalis plc announced today that it has received a $2m milestone under one of its existing research collaborations to discover novel small molecules against an undisclosed target utilising Vernali...

FDA Issues Complete Response Letter on CCP-07 NDA

RNS Number: 9275C Vernalis PLC 21 April 2017 21 April 2017 LSE: VER FDA Issues a Complete Response Letter on CCP-07 NDA Vernalis plc announces today that the US Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) regarding the New Drug Application (NDA) for CCP-07. A CRL is issued by the FDA when it has completed it...

Broker Forecast - Stifel issues a broker note on Vernalis PLC

Stifel today reaffirms its hold investment rating on Vernalis PLC (LON:VER) and cut its price target to 29p (from 31p).

Fundamental DataMore

EPS-3.2
Dividend yield0 %

Equity Research (VER)

edison investment research
Vernalis plc
15/03/2017
Investment into addressing barriers to higher Tuzistra XR prescribing is starting to translate into higher prescription (Rx) rates. Mid-way through the second season post launch, both Rx and sales...
edison investment research
Vernalis plc
05/01/2017
FDA acceptance of the CCP-08 NDA (setting a 4 August 2017 PDUFA date) advances Vernalis towards its goal of building a speciality US franchise of extended release (ER) prescription-only (Rx) cough...
edison investment research
Vernalis plc
21/10/2016
Vernalis marked its transition into a commercial-stage speciality pharma company with the September 2015 US launch of Tuzistra XR, the first product from its extended release (ER) prescription only (...

Latest discussion posts More

  • Now Woody's Buying

    Just me and him then, anyone else? M
    26-Jul-2016
    sound money
  • More Director Buying.

    Wow these guys really believe this is a winner. Glad I bought in last week. M
    9-Jun-2016
    sound money
  • Edison Note - Research Tree

    Read Edison's note on VERNALIS, out this morning, by visiting https://www.research-tree.com/company/GB00B3Y5L754 "Vernalis intends to raise #40m (gross) through the issue of ...
    28-Apr-2016
    FoxRed

Users' HoldingsMore

Users who hold Vernalis also hold..
LLOYDS GRP.34%
VODAFONE GRP.20%
GLAXOSMITHKLINE19%
ROYAL BANK SCOT18%
BP18%

Codes & Symbols

ISINGB00B3Y5L754
SymbolsVER, LSE:VER, VER.L, VER:LN, LON:VER, XLON:VER